Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety Roll-over Study (Rollover) (Rollover)
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Sponsor: Enterin Inc.
Terminated
Poor recruitment/retention due to the pandemic. Data was not analyzed due to early termination.
This PHASE2 trial investigates Constipation and Parkinson Disease and is currently terminated or withdrawn. Enterin Inc. leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Apr 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
▶ Show 7 earlier versions
-
Apr 2022 — Jul 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Feb 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enterin Inc.
For direct contact, visit the study record on ClinicalTrials.gov .